Business Context and Reporting Period
Company: Advanced Biomed Inc. (ADVB)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Six months ended December 31, 2025
Business Overview: Advanced Biomed is a Nevada-based holding company focused on the research and development of microfluidic biochip technologies for precision oncology detection and treatment. The company operates primarily through its subsidiary, Advanced Biomed Inc. (Taiwan). As of the reporting date, the company has no revenue-generating products approved for commercial sale and expects to remain in a state of continuous loss for the next two to three years while pursuing regulatory approvals.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income (Loss) | $6,471,020 | $(1,173,484) |
| Net Income from Continuing Operations | $6,743,499 | $(564,607) |
| Loss from Discontinued Operations | $(272,479) | $(608,877) |
| Total Operating Expenses | $(791,517) | $(507,642) |
| Cash and Cash Equivalents (End of Period) | $2,604,666 | $2,647,656 |
| Net Cash Used in Operating Activities | $(1,123,900) | $(871,521) |
| Total Assets | $10,850,712 | $13,717,716 |
| Total Liabilities | $1,369,070 | $10,240,152 |
| Working Capital | $9,477,991 | $3,143,443 |
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $6.47 million for the six months ended December 31, 2025, compared to a net loss of $1.17 million in the prior year. This reversal is almost entirely attributable to a one-time gain on disposal of subsidiaries of $7,346,684 resulting from the sale of Advanced Biomed (HK) Limited and its subsidiaries.
- Discontinued Operations: The company deconsolidated its Hong Kong subsidiary and related clinical operations in China. Consequently, assets and liabilities previously associated with these entities (approx. $1.5M assets and $8.2M liabilities as of June 30, 2025) were removed from the balance sheet.
- Operating Expenses: Total operating expenses increased by 56% to $791,517 from $507,642. This increase was driven primarily by a 190% rise in General and Administrative expenses (due to increased staff costs and professional fees) and an 11% increase in Research and Development expenses.
- Liquidity Position: Despite the net income, the company utilized $1.12 million in cash from operating activities. However, working capital improved significantly to $9.48 million due to the removal of discontinued operation liabilities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management explicitly states that the company's ability to continue as a going concern is in doubt. The reported net income is non-recurring (driven by asset sales), and the company continues to burn cash from operations ($1.12M outflow). The company relies on future capital raises, related party support, or successful product commercialization to sustain operations.
- Unusual Items: The $7.35 million gain on disposal of subsidiaries is a non-operating, non-recurring item. Excluding this gain, the company would have reported a significant operating loss.
- Capital Resources: The company completed an IPO in March 2025 raising ~$5.49 million net. It also entered into an Equity Line of Credit (ELOC) agreement for up to $25 million. Subsequent to the period end (January 2026), the company issued shares for $248,000 and issued commitment fee shares valued at $500,000 under the ELOC.
- Regulatory Outlook: The company expects no revenue until products receive regulatory approval (NMPA in China, FDA in US, CE in Europe). Several products are in various stages of registration or clinical trials.
- Subsequent Events: Stockholders approved a reverse stock split (ratio 1:2 to 1:100) in January 2026, which had not yet become effective as of the filing date.
Investor Verification Checklist
- Sustainability of Income: Verify that the $6.47M net income is non-recurring and driven by the sale of the HK subsidiary, not operational success.
- Cash Burn Rate: Confirm the company's ability to fund operations given the $1.12M operating cash outflow and the "substantial doubt" regarding going concern status.
- Related Party Transactions: Review the significant amounts due to related parties (approx. $574k current and $114k non-current) and the reliance on related party loans for liquidity.
- Regulatory Milestones: Monitor the status of NMPA approvals for key products (A+Pre, AC-1000, A+LCGuard) as these are prerequisites for any future revenue.
- Reverse Stock Split: Track the implementation of the approved reverse stock split and its impact on share count and liquidity.